CORDIS
EU research results

CORDIS

English EN
Joint training and research on Hedhehog-Gli signalling and its pharmacological modulation for regenerative medicine

Joint training and research on Hedhehog-Gli signalling and its pharmacological modulation for regenerative medicine

Objective

Debilitating degenerative diseases such as non-healing wounds and neurodegeneration do not yet have a cure. They represent a huge unmet medical need worldwide, especially in the aging European population. To reduce the incidence and improve recovery from such ephitelial diseases there is an major need to understand molecular signaling in order to promote stem cell behavior and enhance regeneration and healing. The key objectives of the HEALING network are 1) to train researchers in the fields of molecular signaling, developmental genetics, stem cell biology and small molecule chemistry; 2) to elucidate the mechanisms regulating one of the most promising pathways, Hedgehog-Gli (Hh-Gli) signaling; 3) to manipulate it by the development of specific small molecule agonists for future therapeutic use. Specifically, our research will (a) analyze the basic molecular mechanisms of Hh-Gli signaling in two model organisms and in human cells using leading technologies. In particular, (b) address the mechanisms that ensure controlled Hh-Gli function during skin wound healing and brain repair. (c) develop new small molecule Hh-Gli agonists for use as tools to be used as future therapeutics to enhance wound healing, regeneration and repair in a controlled manner. This network consists of 7 leading academic and research institutions, and 2 biotech companies from 8 European countries. It strengthens existing scientific collaboration, provides complementary expertise and brings together a critical mass for training and research. Additionally, it includes experts from Europe, Canada and Singapore, notably a pioneer in Hh-Gli signaling. HEALING will greatly enhance the training of the next generation of leading scientists in Hh-Gli signaling, stem cells and regenerative medicine. Thus, it will increase the competitiveness of highly skilled staff and of the European biotech industry, which has just recently discovered the role of Hh-Gli signaling in human disease and lags behind the US
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITE DE GENEVE

Address

Rue Du General Dufour 24
1211 Geneve

Switzerland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 081 048

Administrative Contact

Ariel Ruiz I Altaba (Prof.)

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

AnalytiCon Discovery GmbH

Germany

EU Contribution

€ 400 692

CANCER RESEARCH UK LBG

United Kingdom

EU Contribution

€ 401 263

AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS

Spain

EU Contribution

€ 601 736

FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS

Greece

EU Contribution

€ 206 702

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 419 841

PARIS-LODRON-UNIVERSITAT SALZBURG

Austria

EU Contribution

€ 200 345

Phistem Sàrl

Switzerland

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 421 937

Project information

Grant agreement ID: 238186

Status

Closed project

  • Start date

    1 November 2009

  • End date

    31 October 2013

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 3 733 564

  • EU contribution

    € 3 733 564

Coordinated by:

UNIVERSITE DE GENEVE

Switzerland